Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-12G gel for cutaneous lesions in neurofibromatosis type 1 (NEDOC-2)
jRCT2051190008Completed
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of sirolimus in neurofibromatosis type 1 (NF1) (3 arms). Primary endpoint: Response rate based on change in cutaneous tumor volume at week 52. Started May 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on jRCT2051190008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190008.